IP Library Granted Patent US 7,008,942
Granted Patent B2
US 7,008,942 · App. 10/684,746 · Granted Mar 7, 2006

Cytotoxic agents comprising taxanes and their therapeutic use

Assignee: Immunogen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,008,942
App. No.
10/684,746
Granted
Mar 7, 2006
Kind
B2
Abstract

A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.

Claims (40)

1. A compound represented by formula (I):

wherein:

R 1 ″ is H,

R 1 and R 1 ′ are the same or different and are F, NO 2 , CN, Cl, CHF 2 , CF 3 , —NR 7 R 8 or —OR 9 wherein R 7 and R 8 are the same or different and are linear alkyl having 1 to 10 carbon atoms, branched or cyclic alkyl having 3 to 10 carbon atoms, or simple or substituted phenyl or naphthyl and R 9 is linear alkyl having 1 to 10 carbon atoms, or branched or cyclic alkyl having 3 to 10 carbon atoms;

R 2 is —CONR 10 R 11 , wherein R 10 and R 11 are the same or different and are H, linear alkyl having 1 to 10 carbon atoms, branched or cyclic alkyl having 3 to 10 carbon atoms, or aryl;

R 3 is aryl, linear alkyl having 1 to 10 carbon atoms, or branched or cyclic alkyl having 3 to 10 carbon atoms;

R 4 is —OC(CH 3 ) 3 or phenyl;

R 5 is —(CH 2 ) n SZ, —CO(CH 2 ) n SZ, —(CH 2 ) n CH(CH 3 )SZ, —CO(CH 2 ) n CH(CH 3 )SZ, —(CH 2 ) n C(CH 3 ) 2 SZ, —CO(CH 2 ) n C(CH 3 ) 2 SZ, —CONR 12 (CH 2 ) n SZ, —CONR 12 (CH 2 ) n CH(CH 3 )SZ, —CONR 12 (CH 2 ) n C(CH 3 ) 2 SZ, —CO-morpholino-XSZ, —CO-piperidino-XSZ, —CO-piperazino-XSZ, or —CO—N-methylpiperazino-XSZ, wherein

Z is H or SR, wherein R and R 12 are the same or different and are linear alkyl having 1 to 10 carbon atoms, branched or cyclic alkyl having 3 to 10 carbon atoms, or simple or substituted phenyl, naphthyl or heterocyclic, and R 12 in addition can be H,

X is linear alkyl having 1 to 10 carbon atoms or branched alkyl having 3 to 10 carbon atoms, and

n is an integer of ito 10; and

R 6 is H.

2. The compound of claim 1 , wherein one or both of R 1 and R 1 ′ are —OCH 3 or —OCH 2 CH 3 .

3. The compound of claim 1 , wherein R 7 and R 8 each has 1 to 4 carbon atoms.

4. The compound of any one of claims 1 , 2 and 3 , wherein R 7 and R 8 are the same.

5. The compound of claim 1 , wherein R 2 is —CONHCH 2 CH 3 , —CO-morpholino, —CO-piperidino, —CO-piperazino, or —CO—N-methylpiperazino.

6. A cytotoxic composition comprising one or more taxanes convalently bonded to a cell binding agent through a linking group, wherein at least one of said taxanes is a compound represented by formula (I):

wherein:

R 1 ″ is H,

R 1 and R 1 ′ are the same or different and are F, NO 2 , CN, Cl, CHF 2 , CF 3 , —NR 7 R 8 or —OR 9 wherein R 7 and R 8 are the same or different and are linear alkyl having 1 to 10 carbon atoms, branched or cyclic alkyl having 3 to 10 carbon atoms, or simple or substituted phenyl or napthyl and R 9 is linear alkyl having 1 to 10 carbon atoms, or branched or cyclic alkyl having 3 to 10 carbon atoms;

R 2 —CONR 10 R 11 , wherein R 10 and R 11 are the same or different and are H, linear alkyl having 1 to 10 carbon atoms, branched or cyclic alkyl having 3 to 10 carbon atoms, or aryl;

R 3 is aryl, linear alkyl having 1 to 10 carbon atoms, or branched or cyclic alkyl having 3 to 10 carbon atoms;

R 4 is —OC(CH 3 ) 3 or phenyl;

R 5 is —(CH 3 ) n SZ, —CO(CH 2 ) n SZ, —(CH 2 ) n CH(CH 3 )SZ, —CO(CH 2 ) n CH(CH 3 )SZ, —(CH 2 ) n C(CH 3 ) 2 SZ, —CO(CH 2 ) n C(CH 3 ) 2 SZ, —CONR 12 (CH 2 ) n CH(CH 3 )SZ, —CONR 12 (CH 2 ) n C(CH 3 ) 2 SZ, —CO-morpholino-XSZ, —CO-piperidino-XSZ, or —CO—N-methylpiperazino-XSZ wherein:

Z is H or SR, wherein R and R 12 are the same or different and are linear alkyl having 1 to 10 carbon atoms, branched or cyclic alkyl having from 3 to 10 carbon atoms, or simple or substituted phenyl, naphthyl or heterocyclic, and R 12 in addition can be H,

X is linear alkyl having 1 to 10 carbon atoms or branched alkyl having 3 to 10 carbon atoms, and

n is an integer of 1 to 10; and

R 6 is H.

7. The cytotoxic composition of claim 6 , wherein one or both of R 1 and R 1 ′ are —OCH 3 or —OCH 2 CH 3 .

8. The cytotoxic composition of claim 6 , wherein R 7 and R 8 each has 1 to 4 carbon atoms.

9. The cytotoxic composition of any one of claims 6 , 7 and 8 , wherein R 7 and R 8 are the same.

10. The cytotoxic composition of claim 6 , wherein R 2 is —CONHCH 2 CH 3 , —CO-morpholino, —CO-piperidino, —CO-piperazino, or —CO—N-methylpiperazino.

11. The cytotoxic composition of any one of claims 6 , 7 and 8 , wherein the cell binding agent is selected from the group consisting of antibodies, an antibody fragment, interferons, lymphokines, hormones, vitamins, growth factors, colony stimulating factors, and transferrin.

12. The cytotoxic composition of any one of claims 6 , 7 and 8 , wherein the cell binding agent is an antibody.

13. The cytotoxic composition of any one of claims 6 , 7 and 8 , wherein the cell binding agent is a monoclonal antibody.

14. The cytotoxic composition of any one of claims 6 , 7 and 8 , wherein the cell binding agent is an antigen specific antibody fragment.

15. The cytotoxic composition of any one of claims 6 , 7 and 8 , wherein the cell binding agent is sFV, Fab, Fab′, or F(ab′) 2 .

16. The cytotoxic composition of any one of claims 6 , 7 and 8 , wherein the cell binding agent is a growth factor or a colony stimulating factor.

17. A therapeutic composition comprising:

a therapeutically effective amount of the cytotoxic composition of any one of claims 6 , 7 and 8 , and a pharmaceutically acceptable carrier.

Assignments (1)
ADDRESS CHANGE Recorded May 13, 2008
From: IMMUNOGEN, INC.
To: IMMUNOGEN, INC.
Reel/Frame 020930/0905 →
Continuity (6)
Division 1020781400 · Jul 31, 2002
Division 1005902200 · Jan 30, 2002
Division 0993301800 · Aug 21, 2001
Division 0971702600 · Nov 22, 2000
Provisional Application 6016722800 · Nov 24, 1999
Related Publication 20040087649A1 · May 6, 2004